Trial · NCT07191444
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
NCT07191444, Active not recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease. Trials, record NCT07191444. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07191444
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
- NCT number
- NCT07191444
- Status
- Active not recruiting
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Still's Disease, Adult-Onset
- Interventions
- Firsekibart, Anakinra
- First posted
- 2025-09-24
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of subjects achieving clinical inactive disease (CID) at Week 24, where CID is defined as the absence of Still's disease-related symptoms with normal ESR or CRP levels. | At Week 24 from initiation of treatment | |
| Secondary | Proportion of subjects achieving afebrile status with either ≥50% reduction in CRP levels or CRP within normal range at Weeks 2, 4, and 8. | At Weeks 2, 4, and 8 after treatment initiation | Efficacy Endpoints |
| Secondary | Proportion of subjects achieving afebrile status with either ≥70% reduction in CRP levels or CRP within normal range at Week 12. | At Week 12 after treatment initiation | Efficacy Endpoints |
| Secondary | Proportion of subjects achieving afebrile status with either ≥70% reduction in CRP levels or CRP within normal range, and glucocorticoid dose ≤0.2 mg/kg/day at Week 12. | At Week 12 after treatment initiation | Efficacy Endpoints |
| Secondary | Proportion of subjects achieving afebrile status with either ≥70% reduction in CRP levels or CRP within normal range, and glucocorticoid dose ≤0.1 mg/kg/day at Week 12. | At Week 12 after treatment initiation | Efficacy Endpoints |
| Secondary | Proportion of subjects achieving clinical inactive disease (CID) with discontinuation of glucocorticoids | At Week 24 after treatment initiation | Efficacy Endpoints |
| Secondary | Proportion of subjects without disease relapse at Weeks 12 and 24. | At Weeks 12 and 24 after treatment initiation | Efficacy Endpoints |
| Secondary | ACR30, ACR50, ACR70, and ACR90 response rates at Weeks 2, 4, 8, 12, 16, 20, and 24. | At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation | Efficacy Endpoints |
| Secondary | Change from baseline in ferritin levels at Weeks 2, 4, 8, 12, 16, 20, and 24. | At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation | Efficacy Endpoints |
| Secondary | Change from baseline in cytokine levels (including sIL-2R) at Weeks 2, 4, 8, 12, 16, 20, and 24. | At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation | Efficacy Endpoints |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07191444
GET https://conductscience.org/api/trials/v1/NCT07191444/registered